A phase Ib single-arm study of bintrafusp alfa for the treatment of pretreated, locally advanced/unresectable or metastatic urothelial cancer.

被引：2
|
作者：
Grivas, Petros [1 ]
Morales-Barrera, Rafael [2 ]
Sridhar, Srikala S. [3 ]
Loriot, Yohann [4 ]
Van der Heijden, Michiel Simon [5 ]
Galsky, Matt D. [6 ]
Baxter, Dawn [7 ]
Khaled, Ahmed Hussein [7 ]
Hug, Bruce A. [7 ]
机构：
[1] Univ Washington, Fred Hutchinson Canc Res Ctr, Dept Med, Div Oncol,Seattle Canc Care Alliance, Seattle, WA 98195 USA
[2] Univ Autonoma Barcelona, Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Barcelona, Spain
[3] Princess Margaret Canc Ctr, Canc Clin Res Unit, Toronto, ON, Canada
[4] Univ Paris Saclay, Inst Gustave Roussy, Dept Canc Med, Villejuif, France
[5] Netherlands Canc Inst, Amsterdam, Netherlands
[6] Icahn Sch Med Mt Sinai, Tisch Canc Inst, Dept Med, Div Hematol Oncol, New York, NY 10029 USA
[7] GlaxoSmithKline, Collegeville, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 06期
关键词：
D O I：
10.1200/JCO.2021.39.6_suppl.TPS501
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS501
引用
收藏
页数：2
相关论文
共 50 条
  • [41] A Single-Arm, Phase II Study of Apatinib in Refractory Metastatic Colorectal Cancer
    Chen, Xiaofeng
    Qiu, Tianzhu
    Zhu, Yingwei
    Sun, Jing
    Li, Ping
    Wang, Biao
    Lin, Peinan
    Cai, Xiaomin
    Han, Xiao
    Zhao, Fengjiao
    Shu, Yongqian
    Chang, Lianpeng
    Jiang, Hua
    Gu, Yanhong
    ONCOLOGIST, 2019, 24 (07): : 883 - +
  • [42] Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
    Rosenberg, Jonathan E.
    Hoffman-Censits, Jean
    Powles, Tom
    van der Heijden, Michiel S.
    Balar, Arjun V.
    Necchi, Andrea
    Dawson, Nancy
    O'Donnell, Peter H.
    Balmanoukian, Ani
    Loriot, Yohann
    Srinivas, Sandy
    Retz, Margitta M.
    Grivas, Petros
    Joseph, Richard W.
    Galsky, Matthew D.
    Fleming, Mark T.
    Petrylak, Daniel P.
    Perez-Gracia, Jose Luis
    Burris, Howard A.
    Castellano, Daniel
    Canil, Christina
    Bellmunt, Joaquim
    Bajorin, Dean
    Nickles, Dorothee
    Bourgon, Richard
    Frampton, Garrett M.
    Cui, Na
    Mariathasan, Sanjeev
    Abidoye, Oyewale
    Fine, Gregg D.
    Dreicer, Robert
    LANCET, 2016, 387 (10031): : 1909 - 1920
  • [43] The Efficacy and Safety of Anlotinib in Neoadjuvant Treatment of Locally Advanced Thyroid Cancer: A Single-Arm Phase II Clinical Trial
    Huang, Nai-si
    Wei, Wen-jun
    Xiang, Jun
    Chen, Jia-ying
    Guan, Qing
    Lu, Zhong-wu
    Ma, Ben
    Sun, Guo-hua
    Wang, Yu-long
    Ji, Qing-hai
    Wang, Yu
    THYROID, 2021, 31 (12) : 1808 - 1813
  • [44] Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study
    Morris, Van K.
    Salem, Mohamed E.
    Nimeiri, Halla
    Iqbal, Syma
    Singh, Preet
    Ciombor, Kristen
    Polite, Blase
    Deming, Dustin
    Chan, Emily
    Wade, James L.
    Xiao, Lianchun
    Bekaii-Saab, Tanios
    Vence, Luis
    Blando, Jorge
    Mahvash, Armeen
    Foo, Wai Chin
    Ohaji, Chimela
    Pasia, Manolo
    Bland, Gail
    Ohinata, Aki
    Rogers, Jane
    Mehdizadeh, Amir
    Banks, Kimberly
    Lanman, Richard
    Wolff, Robert A.
    Streicher, Howard
    Allison, James
    Sharma, Padmanee
    Eng, Cathy
    LANCET ONCOLOGY, 2017, 18 (04): : 446 - 453
  • [45] MRG002-006: A multicenter phase II clinical trial of MRG002-ADC for unresectable locally advanced or metastatic urothelial cancer.
    Qu, Wang
    Fu, Cheng
    Han, Weiqing
    Sun, Yongkun
    Quan, Jizhong
    Chen, Lijun
    Luo, Hong
    Hu, Hailong
    Niu, Yinong
    Xu, Danfeng
    Liao, Yong
    Chen, Minfeng
    Hu, Changlu
    Liu, Yongda
    Chen, Jimin
    Liu, Lian
    Shi, Benkang
    Chen, Guojun
    Zhou, Fangjian
    Zhou, Ai-Ping
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [46] Safety and Efficacy of Apatinib Monotherapy for Unresectable, Metastatic Esophageal Cancer: A Single-Arm, Open-Label, Phase II Study
    Li Yanwei
    Feng, He
    Ren, Peng
    Yue, Jie
    Zhang, Wencheng
    Tang, Peng
    Shang, Xiaobin
    Pang, Qingsong
    Liu, Dongying
    Chen, Chuangui
    Pan, Zhanyu
    Tao, Yu Zhen
    ONCOLOGIST, 2020, 25 (10): : E1464 - E1472
  • [47] Phase II Study of Gemcitabine, Carboplatin, and Bevacizumab in Patients With Advanced Unresectable or Metastatic Urothelial Cancer
    Balar, Arjun V.
    Apolo, Andrea B.
    Ostrovnaya, Irina
    Mironov, Svetlana
    Iasonos, Alexia
    Trout, Alisa
    Regazzi, Ashley M.
    Garcia-Grossman, Ilana R.
    Gallagher, David J.
    Milowsky, Matthew I.
    Bajorin, Dean F.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06) : 724 - 730
  • [48] Treatment of advanced or metastatic hepatocellular cancer (HCC): Interim analysis of a single-arm phase II study of bevacizumab and RAD001
    Treiber, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [49] ABLE: Phase 2, single-arm, two-stage study of nabpaclitaxel with anti-PD1/PDL1 in advanced urothelial cancer.
    Tsung, Irene
    Green, Edward
    Palmbos, Phillip Lee
    Reichert, Zachery R.
    Vaishampayan, Ulka N.
    Smith, David C.
    Caram, Megan Veresh
    Yentz, Sarah Elizabeth
    Daignault-Newton, Stephanie
    Sloan, Zachery
    Hurley, Laura
    Alva, Ajjai Shivaram
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [50] Results of phase I study of pembrolizumab in combination with binimetinib in patients with unresectable locally advanced or metastatic triple negative breast cancer.
    Chumsri, Saranya
    He, Jun
    Hillman, David
    Weidner, Morgan
    Weidner, Morgan
    Haley, Dana
    Reis, Aline
    Tenner, Kathleen
    Advani, Pooja
    Sideras, Kostandinos
    Moreno-Aspitia, Alvaro
    Perez, Edith
    Knutson, Keith
    CANCER RESEARCH, 2021, 81 (13)
12345